Search Results - James M Markert
- Showing 1 - 16 results of 16
-
1
-
2
-
3
-
4
Preclinical Evaluation of Oncolytic Δγ134.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases by James J. Cody, Pietro Scaturro, Alan B. Cantor, G. Yancey Gillespie, Jacqueline N. Parker, James M. Markert
Published in International Journal of Breast Cancer (2012-01-01)Get full text
Article -
5
Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma by David F. Bauer, Larisa Pereboeva, G. Yancey Gillespie, Gretchen A. Cloud, Osama Elzafarany, Catherine Langford, James M. Markert, Lawrence S. Lamb Jr.
Published in Journal of Immunology Research (2016-01-01)Get full text
Article -
6
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. by David C Gaston, Carl I Odom, Li Li, James M Markert, Justin C Roth, Kevin A Cassady, Richard J Whitley, Jacqueline N Parker
Published in PLoS ONE (2013-01-01)Get full text
Article -
7
Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory by Mohammed G. Ghonime, Josh Jackson, Amish Shah, Justin Roth, Mao Li, Ute Saunders, Jennifer Coleman, G. Yancey Gillespie, James M. Markert, Kevin A. Cassady
Published in Translational Oncology (2018-02-01)Get full text
Article -
8
Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma by Justin T. Low, Michael C. Brown, Zachary J. Reitman, Joshua D. Bernstock, James M. Markert, Gregory K. Friedman, Matthew S. Waitkus, Michelle L. Bowie, David M. Ashley
Published in The Journal of Clinical Investigation (2024-01-01)Get full text
Article -
9
Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma by Jeffrey M. Grimes, Sadashib Ghosh, Shamza Manzoor, Li X. Li, Monica M. Moran, Jennifer C. Clements, Sherrie D. Alexander, James M. Markert, Jianmei W. Leavenworth
Published in Nature Communications (2025-01-01)Get full text
Article -
10
Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. by Corinne E Griguer, Alan B Cantor, Hassan M Fathallah-Shaykh, G Yancey Gillespie, Amber S Gordon, James M Markert, Ivan Radovanovic, Virginie Clement-Schatlo, Chevis N Shannon, Claudia R Oliva
Published in PLoS ONE (2013-01-01)Get full text
Article -
11
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002 by Eric K. Ring, Rong Li, Blake P. Moore, Li Nan, Virginia M. Kelly, Xiaosi Han, Elizabeth A. Beierle, James M. Markert, Jianmei W. Leavenworth, G. Yancey Gillespie, Gregory K. Friedman
Published in Molecular Therapy: Oncolytics (2017-12-01)Get full text
Article -
12
Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms by Colin H. Quinn, Janet R. Julson, Michael H. Erwin, Hooper R. Markert, Larua V. Bownes, Jerry E. Stewart, Sorina Shirley, Karina J. Yoon, Jamie M. Aye, James M. Markert, Elizabeth A. Beierle
Published in Scientific Reports (2025-04-01)Get full text
Article -
13
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. by Lauren A Gillory, Michael L Megison, Jerry E Stewart, Elizabeth Mroczek-Musulman, Hugh C Nabers, Alicia M Waters, Virginia Kelly, Jennifer M Coleman, James M Markert, G Yancey Gillespie, Gregory K Friedman, Elizabeth A Beierle
Published in PLoS ONE (2013-01-01)Get full text
Article -
14
The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canin... by M. R. Chambers, R. Timothy Bentley, David K. Crossman, Jeremy B. Foote, Jey W. Koehler, James M. Markert, Nidal B. Omar, Simon R. Platt, D. Mitchell Self, Andy Shores, Donald C. Sorjonen, Alicia M. Waters, Amy B. Yanke, G. Yancey Gillespie
Published in Frontiers in Surgery (2020-08-01)Get full text
Article -
15
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition by Roman L. Travis, BS, Samuel R. Marcrom, MD, Matthew H. Brown, BS, Mayank P. Patel, MD, James M. Markert, MD, MPH, Kristen O. Riley, MD, Robert Conry, MD, Christopher D. Willey, MD, PhD, Markus Bredel, MD, PhD, John B. Fiveash, MD
Published in Advances in Radiation Oncology (2021-01-01)Get full text
Article -
16
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity by Upasana Sahu, Matthew P. Mullarkey, Sara A. Murphy, Joshua C. Anderson, Vasanta Putluri, Abu Hena Mostafa Kamal, Jun Hyoung Park, Tae Jin Lee, Alexander L. Ling, Benny A. Kaipparettu, Ashok Sharma, Nagireddy Putluri, Pamela L. Wenzel, Christopher D. Willey, E. Antonio Chiocca, James M. Markert, Balveen Kaur
Published in Nature Communications (2025-04-01)Get full text
Article
